Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Non-hodgkin Lymphoma, Unspecified
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Histologically confirmed FL or DLBCL fro the following diagnoses by 2016 WHO classification of lymphoid neoplasms 2) Must have received at least one prior systemic treatment regimen containing an anti-CD20-directed therapy for DLBCL or FL. Patients must have either relapsed or have become refractory to a prior regimen as defined below. 3) Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
  

You may not be eligible for this study if the following are true:

• 1) Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies 2) Prior treatment with polatuzumab vedotin 3) Current > Grade 1 peripheral neuropathy 4) Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment